= Solution
\b[Central hypothesis and objectives.] PUF50 participates in one or more <protein> assemblies whose composition or activity affects <Wnt signalling>. The proposal should distinguish membership, direct binding and causal pathway regulation. The three aims are to nominate plausible partners, identify reproducible cellular complexes, and test whether a supported interaction explains the phenotype.
\b[Computational starting point.] Inspect the verified PUF50 sequence for <protein domains>, localization signals, conserved residues and predicted disordered regions. Use <sequence alignment> and <orthology> to compare well-annotated homologues, recording uncertainty in functional transfer. Public interaction and expression resources can nominate partners expressed in the experimental cell line. Structural predictions can prioritize testable interfaces, but a confident fold alone does not establish a cellular interaction or tumour-suppressor function.
\b[Discovery <proteomics>.] Use <affinity purification-mass spectrometry> to compare PUF50-associated material with matched negative controls across independent <biological replicates>. An endogenous or functionally validated tagged preparation is preferable to assuming that strong overexpression preserves normal localization and complex <stoichiometry>. Tag-only controls, input abundance measurements and an unrelated bait help distinguish reproducible association from abundant or sticky contaminants. Quantitative enrichment should be evaluated together with replicate consistency and a controlled <false discovery rate>.
Complexes may vary with pathway state. Compare a relevant baseline and a defined Wnt-responsive state, checking that changes in recovered partner abundance are not explained solely by input abundance, cell number or viability. If transient or compartmentalized partners are missed, <proximity labeling> can provide complementary neighbourhood evidence. Its hits should be labelled as proximity associations rather than automatically promoted to direct complex subunits.
\b[Independent validation and mechanism.] Validate leading associations by reciprocal <co-immunoprecipitation> and localization evidence. Where a direct interaction is important to the proposed mechanism, test it with an independent assay suited to the relevant <protein domains>. A genetic perturbation and rescue comparison can ask whether loss of PUF50 changes pathway output and whether restoring PUF50 restores it. Compare pathway-proximal measurements with downstream transcription and longer-term growth phenotypes, because a growth defect alone is not specific to Wnt regulation.
A separation-of-function comparison is especially informative: a PUF50 variant that retains abundance and localization but loses a supported partner association could help connect the interaction to function. This interpretation requires checking folding and stability, since an inactive misfolded <protein> does not isolate one interface's role. Genetic interaction analysis can then place PUF50 relative to known pathway components without treating every correlated expression change as a direct target.
\b[Analysis, deliverables and alternatives.] Integrate quantitative interaction evidence, localization and perturbation responses into an annotated <protein interaction network>, retaining evidence type on each edge. Report <effect sizes> and uncertainty, include unsuccessful validation, and release analysis code with processed data. A negative stable-complex result would motivate a transient or condition-specific interaction hypothesis rather than proving that PUF50 acts alone. The principal deliverable is a ranked, experimentally qualified set of complexes and a causal test of the most supported pathway mechanism.
Back to article page
